Conditions: B-cell Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
Keywords: PCI-32765 Lymphoma, B-Cell Leukemia, Lymphoid Leukemia, B-Cell Bruton's Tyrosine Kinase
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 133
Healthy volunteers: no

Brief summary:
The purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: PCI-32765
Intervention descriptions: intervention 1: 420 mg daily or 840 mg daily

Protocol document: